54 related articles for article (PubMed ID: 2618764)
21. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors.
Goosey MW; Doggett NS
Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954
[No Abstract] [Full Text] [Related]
22. [Neurotensin-like oligopeptides as potential antipsychotics: effect on dopamine system].
Kost NV; Meshavkin VK; Batishcheva EIu; Sokolov OIu; Andreeva LA; Miasoedov NF
Eksp Klin Farmakol; 2011; 74(10):3-6. PubMed ID: 22238978
[TBL] [Abstract][Full Text] [Related]
23. Conversion of dopamine D1 receptors from high to low affinity for dopamine.
Seeman P; Ulpian C; Grigoriadis D; Pri-Bar I; Buchman O
Biochem Pharmacol; 1985 Jan; 34(1):151-4. PubMed ID: 3881100
[No Abstract] [Full Text] [Related]
24. A mosaic-like distribution of dopamine receptors in rat neostriatum and its relationship to striosomes.
Loopuijt LD; Sebens JB; Korf J
Brain Res; 1987 Mar; 405(2):405-8. PubMed ID: 3567618
[TBL] [Abstract][Full Text] [Related]
25. Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone.
Sokoloff P; Martres MP; Schwartz JC
Naunyn Schmiedebergs Arch Pharmacol; 1980; 315(2):89-102. PubMed ID: 7207647
[No Abstract] [Full Text] [Related]
26. Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
Neumeyer JL; Arana GW; Ram VJ; Kula NS; Baldessarini RJ
J Med Chem; 1982 Aug; 25(8):990-2. PubMed ID: 7120288
[TBL] [Abstract][Full Text] [Related]
27. Centrally administered galanin reduces dopamine utilization in the median eminence and increases dopamine utilization in the medial neostriatum of the male rat.
Jansson A; Fuxe K; Eneroth P; Agnati LF
Acta Physiol Scand; 1989 Feb; 135(2):199-200. PubMed ID: 2466392
[No Abstract] [Full Text] [Related]
28. High-affinity 3H-dopamine receptors (D3 sites) in human and rat brain.
List S; Titeler M; Seeman P
Biochem Pharmacol; 1980 Jun; 29(11):1621-2. PubMed ID: 7396995
[No Abstract] [Full Text] [Related]
29. Dopamine receptors on prefrontal neurons.
Yano H; Tanaka E; Higashi H; Nishi S
Kurume Med J; 1989; 36(3):151-4. PubMed ID: 2635248
[No Abstract] [Full Text] [Related]
30. Neurotensin and its amide analogue [Gln4]-neurotensin: effects on brain monoamine turnover.
García-Sevilla JA; Magnusson T; Carlsson A; Leban J; Folkers K
Naunyn Schmiedebergs Arch Pharmacol; 1978 Dec; 305(3):213-8. PubMed ID: 740049
[TBL] [Abstract][Full Text] [Related]
31. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection.
Fuxe K; Andersson K; Locatelli V; Agnati LF; Hökfelt T; Skirboll L; Mutt V
Eur J Pharmacol; 1980 Oct; 67(2-3):329-31. PubMed ID: 7461038
[No Abstract] [Full Text] [Related]
32. [Effect of neurotensin on thyrotropin secretion in rats: in vivo studies].
Sadowska-Krowicka H; Krowicki Z
Endokrynol Pol; 1986; 37(4):179-88. PubMed ID: 3830079
[No Abstract] [Full Text] [Related]
33. Modification of dopaminergic receptor sensitivity in rat brain after amygdaloid kindling.
Gee KW; Hollinger MA; Bowyer JF; Killam EK
Exp Neurol; 1979 Dec; 66(3):771-7. PubMed ID: 488251
[No Abstract] [Full Text] [Related]
34. An hypothesis of the molecular structure of the dopamine receptor.
Smythies JR
Med Hypotheses; 1981 Dec; 7(12):1449-56. PubMed ID: 7334949
[TBL] [Abstract][Full Text] [Related]
35. Genetic aspects of dopamine receptor binding in the mouse and rat brain: an overview.
Vadasz C; Laszlovszky I; De Simone PA; Fleischer A
J Neurochem; 1992 Sep; 59(3):793-808. PubMed ID: 1494909
[No Abstract] [Full Text] [Related]
36. Human brain receptors,V. Binding and message.
Meador-Woodruff JH; Watson SJ; Tamminga CA
Am J Psychiatry; 1994 Jun; 151(6):804. PubMed ID: 8184989
[No Abstract] [Full Text] [Related]
37. Targeting neurotransmitter receptors with nanoparticles in vivo allows single-molecule tracking in acute brain slices.
Varela JA; Dupuis JP; Etchepare L; Espana A; Cognet L; Groc L
Nat Commun; 2016 Mar; 7():10947. PubMed ID: 26971573
[TBL] [Abstract][Full Text] [Related]
38. The manifold actions of neurotensin, a trophotropic agent.
Prange AJ
Ann N Y Acad Sci; 1992; 668():298-306. PubMed ID: 1463272
[No Abstract] [Full Text] [Related]
39. The role of neurotensin in central nervous system pathophysiology: what is the evidence?
St-Gelais F; Jomphe C; Trudeau LE
J Psychiatry Neurosci; 2006 Jul; 31(4):229-45. PubMed ID: 16862241
[TBL] [Abstract][Full Text] [Related]
40. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain.
von Euler G; Meister B; Hökfelt T; Fuxe K
Acta Physiol Scand; 1989 Oct; 137(2):309-10. PubMed ID: 2618764
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
